Suppliers / Vovantis Laboratories

Vovantis Laboratories

India 2 duplicate records merged Updated 9 July 2026

Vovantis Laboratories is a finished-dose manufacturer based in India. It appears in 36 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO), EDE (AE) and ARCSA (EC). Its GMP standing is certified by CDSCO (India), US FDA and NAFDAC (NG). Its most recent recorded inspection, by US FDA, closed on 24 May 2024 as NAI. Customs aggregates show $1.6M of exports covering 92 molecules to 8 destinations in 2025.

0
active US DMFs
0
valid CEPs
6
registered plants 1 with an FDA FEI number
36
filings across 4 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 24 May 2024 NAI US FDA
  • 9 June 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
VADODARA, United Arab Emirates Not on file
Ranoli, United Arab Emirates Not on file
Vadodara, India 3008132370
ay stationvillage ranoli 391 350vadodara, India Not on file
vad odara 391 350, India Not on file
Gujarat India, Nigeria Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 22 None
EDE (AE) 8 None
ARCSA (EC) 3 None
NAFDAC (NG) 3 1
CDSCO (India) None 4
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $397K 3
2025 Not reported $1.6M 8
2024 Not reported $1.6M 5
2023 Not reported $846K 2

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Vovantis Laboratories comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 24 May 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts